Biogen’s 2002 Press Releases

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission (“SEC”) or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press releases and filings with the SEC.

2003 |2002 |2001 | 2000 Back to main index

 

12/19/2002

BIOGEN APPOINTS BOB HAMM SENIOR VICE PRESIDENT OF NORTH AMERICAN COMMERCIAL OPERATIONS

12/17/2002

BIOGEN SCIENTISTS ADVANCE UNDERSTANDING OF INFLAMMATORY BOWEL DISEASE WITH NEW DISCOVERIES AND IDENTIFY POTENTIAL NOVEL THERAPEUTIC APPROACHES

12/16/2002

BIOGEN NAMES WHAIJEN SOO, M.D., Ph.D. AS SENIOR VICE PRESIDENT, MEDICAL RESEARCH
11/26/2002

NEUROLOGY STUDY FINDS APPROVED DOSE OF AVONEX® (Interferon beta-1a) EQUALLY EFFECTIVE AS HIGHER DOSE IN TREATING RELAPSING MULTIPLE SCLEROSIS

11/22/2002

EARLY RESULTS SUGGEST ALEFACEPT PLUS LIGHT THERAPY MAY CLEAR PSORIASIS

11/14/2002

FDA APPROVES LABELING CHANGE FOR BIOGEN’S AVONEX® (Interferon beta-1a) TO INDICATE LOWER OCCURRENCE OF NEUTRALIZING ANTIBODIES

10/18/2002

Biogen and Schering-Plough Settle Royalty Payment Arbitration

10/18/2002

BIOGEN ANNOUNCES THIRD QUARTER 2002 EARNINGS

09/12/2002

Biogen’s AMEVIVE® (alefacept) Application On Track for Early 2003 Approval

08/26/2002

Biogen Statement on The Wall Street Journal Generic Drug Story

08/22/2002

BIOGEN OPENS COMMUNITY LABORATORY, STATE-OF-THE-ART TEACHING FACILITY

07/30/2002

BIOGEN ANNOUNCES RESULTS FROM CDP 571 STUDIES IN CROHN’S DISEASE

07/29/2002

BIOGEN SCIENTISTS PART OF TEAM THAT ADVANCES UNDERSTANDING OF ANGIOGENESIS AND INFLAMMATION

07/25/2002

BIOGEN UNVEILS ENHANCED MULTIPLE SCLEROSIS WEB SITE

07/18/2002

BIOGEN ANNOUNCES SECOND QUARTER 2002 EARNINGS PER SHARE OF $0.29

07/16/2002

JIM VINCENT RETIRES AND JIM MULLEN ELECTED CHAIRMAN OF THE BOARD OF DIRECTORS OF BIOGEN

07/09/2002

BIOGEN NAMES CHRISTINE CARBERRY AS VICE PRESIDENT, PROGRAM AND ALLIANCE MANAGEMENT

06/13/2002

BIOGEN RECEIVES “COMPLETE RESPONSE” LETTER FROM FDA ON AMEVIVE® (alefacept) APPLICATION

06/07/2002

BIOGEN ANNOUNCES REVISED 2002 FINANCIAL GUIDANCE

05/23/2002

FDA Advisory Committee Recommends Approval of Biogen’s AMEVIVE®

05/21/2002

BIOGEN NAMES NICOLAS BARTHELEMY AS VICE PRESIDENT, MANUFACTURING AND GENERAL MANAGER, RESEARCH TRIANGLE PARK, NORTH CAROLINA

05/20/2002

BIOGEN ANNOUNCES $25,000 ANNUAL COMMITMENT TO CROWN PRINCE FREDERIK FUND

05/20/2002

BIOGEN’S AVONEX® (Interferon beta-1a) APPROVED IN EUROPE FOR TREATMENT OF PATIENTS AT HIGH RISK FOR DEVELOPING MULTIPLE SCLEROSIS

05/16/2002

AVONEX® (Interferon beta-1a) GAINS MEDICARE COVERAGE

05/10/2002

BIOGEN NAMES MICHAEL KOWOLENKO, PH.D. AS VICE PRESIDENT, GLOBAL QUALITY

05/08/2002

BIOGEN DEDICATES TWO NEW WORLD-CLASS FACILITIES IN RESEARCH TRIANGLE PARK, NORTH CAROLINA

05/06/2002

BIOGEN REVAMPS MULTIPLE SCLEROSIS WEB SITE

05/01/2002

BIOGEN LAUNCHES PSORIASISSUPPORT.COM

04/24/2002

CELLTECH AND BIOGEN ANNOUNCE WORLD-WIDE COLLABORATION, TO DEVELOP AND COMMERCIALISE PHASE III CROHN’S DISEASE PRODUCT

04/24/2002

BIOGEN ANNOUNCES FIRST QUARTER 2002 EARNINGS PER SHARE OF $0.47

04/18/2002

New Long-Term Data on AVONEX® (Interferon beta-1a)

04/16/2002

Biogen Launches First Long-Term Study Comparing AVONEX® (Interferon beta-1a) and REBIF® In Treatment of Multiple Sclerosis

04/08/2002

BIOGEN NAMED PROJECT EXCELLENCE AWARD WINNER

04/02/2002

BIOGEN NAMES JOHN PALMER AS SENIOR VICE PRESIDENT, CORPORATE DEVELOPMENT

04/01/2002

BIOGEN ANNOUNCES MEETING OF FDA ADVISORY COMMITTEE TO REVIEW AMEVIVE® (alefacept) FOR TREATMENT OF PSORIASIS

03/26/2002

BIOGEN AND MIT ESTABLISH TOXICOLOGY FELLOWSHIP PROGRAM

03/25/2002

ECKHARD PFEIFFER ELECTED TO BIOGEN BOARD OF DIRECTORS

03/12/2002

FDA SAYS NO CLINICAL SUPERIORITY IN LABELING FOR REBIF®

03/08/2002

BIOGEN’S AVONEX® READY TO COMPETE AGAINST THIRD INTERFERON

02/22/2002

Biogen to Present at the Lehman Brothers’ Global Health Care Conference

01/24/2002

BIOGEN SETTLES PATENT LITIGATION WITH BERLEX LABORATORIES

01/24/2002

BIOGEN DELIVERS ON OPERATING EARNINGS GUIDANCE OF $1.90 PER SHARE AFTER ONE-TIME CHARGES


2003 |2002 | 2001 | 2000 Back to main index